1 citations
,
January 2024 in “Curēus” This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly.
February 2024 in “Recima21” This study explored the connections between Covid-19 and hair loss issues like telogen effluvium and alopecia areata, highlighting the virus's potential trigger effect and underscoring the importance of comprehensive post-Covid-19 treatment strategies that consider immune, psychological, and hair cycle factors.
June 2025 in “Cancer Management and Research” This study found that scalp cooling resulted in visible hair retention in 53% of breast cancer patients undergoing Epirubicin/Cyclophosphamide and Paclitaxel treatment, with factors like hair bulb diameter, shaft diameter, and anagen rate significantly predicting outcomes.
April 2023 in “Voprosy kurortologii fizioterapii i lechebnoĭ fizicheskoĭ kultury” This study reported that 19.8% of patients experienced telogen hair loss after COVID-19, with most cases occurring 3 to 6 months post-recovery, and noted a rapid progression in patients with androgenetic alopecia, as well as cases of alopecia areata and cicatricial alopecia linked to COVID-19.
December 2021 in “Journal of The American Academy of Dermatology” This article discusses post-COVID-19 hair loss, highlighting potential misdiagnoses between different types and the expanded role of dermatologists; no new clinical findings are reported.